• Contraindications
    • Patients with hypersensitivity to GnRH agonists or any of the excipients in LUPRON DEPOT.
    • Women who are or may become pregnant.

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month,
    and 45 mg for 6-month [package insert].

  • Before Starting
    • Hyperglycemia and increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in men receiving a GnRH agonist and manage hyperglycemia or diabetes.
    • An increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists in men, although the risk appears low. Evaluate the risks carefully, including cardiovascular risk factors, when determining prostate cancer treatment. Patients receiving a GnRH agonist should be monitored for signs and symptoms of cardiovascular disease and managed appropriately.
    • Androgen deprivation therapy (ADT) may prolong the QT/QTc interval. Consideration should be given to whether the benefits of ADT outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Correct electrolyte abnormalities and consider periodic monitoring of electrocardiograms and electrolytes.
    • Postmarketing reports of convulsions have been observed in patients on leuprolide acetate therapy, including patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and in patients on concomitant medications associated with convulsions, such as bupropion and SSRIs. Convulsions have also been reported in the absence of any of the conditions mentioned above.

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for 6-month [package insert].

  • What Your
    Patients Can Expect
    • LUPRON DEPOT causes an initial increase in serum testosterone (~50% above baseline) during the first few weeks of treatment. This initial increase can cause:
      • Transient worsening of symptoms, or additional signs and symptoms of prostate cancer.
      • Temporary increase in bone pain in a small number of patients, which can be managed symptomatically.
      • Isolated cases of ureteral obstruction and spinal cord compression, which may contribute to paralysis with or without fatal complications. Observe patients with vertebral metastasis and/or urinary tract obstruction closely.
    • Periodic monitoring of serum testosterone and PSA levels is recommended.
    • LUPRON DEPOT may cause impotence.

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for 6-month [package insert].

  • Side Effects
    • In controlled clinical trials of advanced prostatic cancer patients receiving LUPRON DEPOT, the following adverse events occurred
      in >10% of patients:
      • LUPRON DEPOT 7.5 mg for 1-month administration: hot flashes/sweats, general pain, edema, urinary disorders, GI disorders, and respiratory disorders.
      • LUPRON DEPOT 22.5 mg for 3-month administration: hot flashes/sweats, general pain, testicular atrophy, GI disorders, urinary disorders, injection site reactions, and joint disorders.
      • LUPRON DEPOT 30 mg for 4-month administration: hot flashes/sweats, injection site reactions, general pain, edema, urinary disorders, joint disorders, GI disorders, asthenia, flu syndrome, skin reactions, and headache.
      • LUPRON DEPOT 45 mg for 6-month administration: hot flush/flushing, upper respiratory tract infection/influenza-like illness, injection site pain/discomfort, and fatigue/lethargy.

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for 6-month [package insert].

  • Helpful Resources

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

    If your patients cannot afford their medication, contact www.pparx.org for assistance.

    View the full Prescribing Information for LUPRON
    DEPOT at http://www.rxabbvie.com/pdf/
    lupronuro_pi.pdf
    .

    Reference:
    LUPRON DEPOT 7.5 mg for
    1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for 6-month [package insert].

Print
Safety Facts
  • LUPRON DEPOT 7.5 mg for 1-month, 22.5 mg for
    3-month, 30 mg for 4-month, and 45 mg for
    6-month administration are indicated for the palliative treatment of advanced prostatic cancer.
  • LUPRON DEPOT is a gonadotropin-releasing hormone (GnRH) agonist administered as a single intramuscular injection under the supervision of a physician.

Reference:
LUPRON DEPOT 7.5 mg for 1-month, 22.5 mg for
3-month, 30 mg for 4-month, and 45 mg for
6-month [package insert].

HCP support iconCreating Awareness and Supporting
Prostate Cancer Patients

AbbVie supports initiatives that increase awareness of prostate cancer

Prostate Cancer Awareness Month—Every September, we provide healthcare professionals with all kinds of materials they can use in their practices to make patients more aware of and educated about prostate cancer. Materials include brochures, posters, and tabletop easels.

Contact your AbbVie Representative for information on support materials for Prostate Cancer Awareness Month.

ZERO is a patient advocacy organization dedicated to reducing, alleviating and eventually ending prostate cancer. AbbVie is proud to be the Premier Partner of its nationwide race and event series, the ZERO Prostate Cancer Challenge. Events in more than 30 cities across the country raise awareness and funds for free testing and research.
Find out how to get involved here.

Educational booklets on prostate cancer and treatment

These booklets were created for your use as educational handouts for your patients. Contact your AbbVie Representative to get copies for distribution at your practice.

100 Questions & Answers About
Prostate Cancer
is a comprehensive
book by Pamela Ellsworth, MD, which
answers almost any question a patient
might have about the disease and treatment.

Prostate Cancer Fast Facts contains quick
answers to common questions.

Treating Advanced Prostate Cancer With
Lupron Depot
is our helpful, informative
brochure for patients. It’s available in both
English and Spanish.

Promoting Wellness For Prostate
Patients
by Mark Moyad, MD, is a
comprehensive prostate cancer and
health resource. Patients can learn about
diagnosis, treatment, diet, managing side
effects, and more.

Disease state awareness brochures in
English and Spanish
help your patients
become informed. They include a
treatment journal that helps patients track
their medications and doctor visits.

Prostate cancer support groups

AbbVie and Lupron Depot have partnered with prostate cancer support groups for many years. These organizations can be an invaluable resource for your patients grappling with disease and treatment issues, so be sure to pass along their contact information.

Us TOO International
Prostate Cancer Education
& Support Network

www.ustoo.org

Us TOO is a nonprofit umbrella for 325 support group chapters worldwide, providing patients and families with peer-to-peer support and information.

 

Tell your patients about the Lupron Depot
advanced prostate cancer patient site

On the patient side of this site, we answer your patients’ questions about advanced prostate cancer, Lupron Depot, the treatment regimen, insurance coverage, and support. Be sure to let your patients know about this resource at

www.lupronprostatecancer.com